Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Core Study
Diagnosis of relapsing multiple Sclerosis (MS)
Patients with at least two documented relapses in the previous 2 years or one documented relapse in the last year
Patients with an Expanded Disability Status Scale (EDSS) score of 0-6
Extension Study
A positive Gd-enhanced MRI scan at screening (in case the first MRI scan obtained at screening was negative, a second scan could have been obtained 1 month later)
Neurologically stable with no evidence of relapse within 30 days prior to randomization,or during the Screening and Baseline periods.
Female patients either post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control. Females of childbearing potential with a negative pregnancy test at baseline prior to entry into the treatment period.
You may not be if
Core Study
Patients with other chronic disease of the immune system, malignancies, pulmonary or heart disease, etc
Pregnant or nursing women
Extension Study
Patients who had permanently discontinued study drug prior to the Month 6 visit of the core study
Patients with diabetes mellitus (to reduce the risk of ME), and therefore ongoing patients with diabetes mellitus or who developed diabetes mellitus were discontinued from the study)
Clareo Health | Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
